Cargando…

Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622297/ https://www.ncbi.nlm.nih.gov/pubmed/35869958 http://dx.doi.org/10.1093/eurheartj/ehac428

Ejemplares similares

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled( )
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
por: Zannad, Faiez, et al.
Publicado: (2022)

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
por: Packer, Milton, et al.
Publicado: (2021)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Publicado: (2023)

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
por: Zannad, Faiez, et al.
Publicado: (2020)

Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry
Publicado: (2023)

Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
por: Packer, Milton, et al.
Publicado: (2020)

Corrigendum to: Pulmonary Hypertension in Heart Failure Patients
por: Rao, Sriram D, et al.
Publicado: (2020)

Corrigendum to: Clinical case: heart failure and ischaemic heart disease
Publicado: (2020)

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
por: Anker, Stefan D., et al.
Publicado: (2022)

Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial
por: Anker, Stefan D., et al.
Publicado: (2020)

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
por: Butler, Javed, et al.
Publicado: (2021)

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Lam, Carolyn S P, et al.
Publicado: (2021)

Corrigendum to: Care plans for the older heart failure patient
Publicado: (2019)

Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Corrigendum to: Renal function, electrolytes and congestion monitoring in heart failure
Publicado: (2019)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023)

Hearing Loss and Physical Functioning Among Adults with Heart Failure: Data from NHANES [Corrigendum]
Publicado: (2020)

Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled
por: Verma, Subodh, et al.
Publicado: (2023)

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Corrigendum to “Sleep-Disordered Breathing in Patients with Heart Failure: New Trends in Therapy”
por: Kazimierczak, Anna, et al.
Publicado: (2015)

Corrigendum to “Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure”
por: Bárány, Tamás, et al.
Publicado: (2019)

Corrigendum to: Global burden of heart failure: a comprehensive and updated review of epidemiology
Publicado: (2023)

Corrigendum to: Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)
Publicado: (2023)

Corrigendum to: VEGF-B hypertrophy predisposes to transition from diastolic to systolic heart failure in hypertensive rats
Publicado: (2023)

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
por: Williams, David M., et al.
Publicado: (2020)

Corrigendum to: Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
Publicado: (2022)

Corrigendum to: Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
Publicado: (2023)

Corrigendum to “Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure”
por: Park, Bumsoo, et al.
Publicado: (2017)

Corrigendum to “Antiapoptosis and Antifibrosis Effects of Qishen Granules on Heart Failure Rats via Hippo Pathway”
por: Zhang, Jian, et al.
Publicado: (2020)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Publicado: (2021)

Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial
por: Packer, Milton, et al.
Publicado: (2021)

Corrigendum to: Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models
Publicado: (2022)

Corrigendum to “Circulating microRNAs as Novel Potential Biomarkers for Left Ventricular Remodeling in Postinfarction Heart Failure”
por: Gao, Guangyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3k2adpq26g78g1st998fn50oli